New Drug Application Rolling Submission for Alagille Syndrome Planned to Begin in Third Quarter 2020 Cash, Cash Equivalents and Investments Balance of $140.0 million before gross proceeds of $48.0 million from a follow-on public offering in January 2020 On Track for PFIC Phase 3 Top-Line Data and

FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 18, 2020-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 14, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the promotion of Ian Clements to Chief Financial

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public offering of 2,400,000 shares